Android app Apple app link

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

By Yahoo! Finance   |   1 year ago
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

The Phase 3 ICONIC clinical development program includes studies evaluating icotrokinra in moderate to severe plaque psoriasis (PsO) and psoriatic arthritis. ICONIC-LEAD and ICONIC-TOTAL are randomized controlled trials assessing safety and efficacy, with other studies ongoing.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.